Regulatory T Cells: The Immune System’s Peacekeepers

The Peacekeepers Within

In the intricate landscape of the human immune system, an extraordinary cellular guardian works tirelessly to maintain balance—the regulatory T cell. This year, the Nobel Prize in Physiology or Medicine honored three scientists who uncovered these cellular protectors: Americans Mary Brunkow and Fred Ramsdell, and Japan’s Shimon Sakaguchi. Their collective work revealed how a special group of cells prevents the immune system from turning against the body, opening new pathways to combat autoimmune diseases and cancer .

What Are Regulatory T Cells?

Regulatory T cells (Tregs) are a specialized subset of white blood cells that serve as the immune system‘s “security guards” . They act as a sophisticated braking system, preventing excessive immune responses that could otherwise damage healthy tissues.

The immune system is our primary defense against invading pathogens, such as the microbes that cause infections. Its most powerful weapons are T cells, which seek out, identify, and destroy invading germs or cancerous cells throughout the body . However, T cells sometimes misidentify their targets and attack healthy cells, leading to autoimmune diseases such as type 1 diabetes and lupus .

Regulatory T cells function as the immune system’s “peacekeepers” . Jonathan Fisher, head of the Innate Immune Engineering Laboratory at University College London, explains: “They put the brakes on the immune system to prevent it from attacking something that it shouldn’t” .

For decades, scientists believed that this crucial regulatory role was performed entirely by the thymus, a small gland in the upper chest where T cells develop . The thymus eliminates T cells whose receptors match healthy cells, preventing “friendly fire.” But what happens when rogue T cells slip through this screening process? That is where regulatory T cells come into play.

The Nobel-Winning Discovery

The journey to understanding regulatory T cells was marked by persistent investigation and challenges to conventional wisdom.

In the 1980s, while most researchers had abandoned the idea of peripheral immune regulation, Sakaguchi persisted with his hypothesis. His team conducted a pivotal experiment: they extracted T cells from one mouse and injected them into another that had no thymus. The recipient mouse became protected against autoimmune diseases, demonstrating that something beyond the thymus must be capable of controlling self-attacking T cells .

Approximately a decade later, Brunkow and Ramsdell investigated why male mice from a mutated strain called “scurfy” survived only a few weeks. In 2001, they proved that a mutation in the FOXP3 gene caused both the scurfy condition in mice and a rare human autoimmune disease called IPEX .

Scientists, including Sakaguchi, subsequently demonstrated that FOXP3 controls the development of regulatory T cells . In 2003, Sakaguchi’s team connected these findings, showing that FOXP3 acts as the “master switch” governing Treg development and function . This connection established the molecular foundation of regulatory T cells and marked the beginning of systematic exploration of their functions and mechanisms.

Stem Cell Transplantation and Tregs’ Protective Role

Stem cell transplantation, particularly allogeneic hematopoietic stem cell transplantation (allo-HSCT), can be a life-saving treatment for leukemia and other blood cancers . However, the procedure carries significant risks, most notably graft-versus-host disease (GVHD), in which donor immune cells attack the recipient’s tissues .

Regulatory T cells play a crucial role in preventing these devastating complications. Recent research has revealed how these cellular guardians maintain immune balance even in the challenging context of transplantation.

A groundbreaking study published in Science Advances by a team led by Academician Huang Xiaojun and Professor Zhao Xiangyu of Peking University People’s Hospital identified a previously unknown type of regulatory T cell—CD8+HLA-DR+CD27+ T cells (CD8 Trp cells) . These natural regulatory T cell precursors are present in healthy individuals and play a vital role in restoring immune homeostasis after stem cell transplantation.

The research team found that CD8 Trp cells are present naturally in healthy individuals and in patients who have successfully restored immune homeostasis after allogeneic hematopoietic stem cell transplantation, accounting for approximately 1%-3% of CD8+ T cells .

In experimental models, these cells demonstrated remarkable therapeutic potential. In xenogeneic graft-versus-host disease (x-GVHD) mouse models, CD8 Trp cells reduced donor T cell attacks on host tissues, lowering GVHD mortality from 70% to 30% while preserving the graft-versus-leukemia effect . This dual function—suppressing harmful immune responses while maintaining anti-tumor capacity—makes them particularly promising for clinical applications.

The Foundation of a New Research Field

The discovery of regulatory T cells has fundamentally transformed immunology, establishing an entirely new research field focused on peripheral immune tolerance . This concept refers to how the body maintains non-reactivity to self-antigens or harmless antigens in peripheral tissues such as the lymph nodes and spleen, working alongside “central tolerance” to prevent autoimmune diseases or allergic reactions .

The implications of this discovery extend far beyond autoimmune diseases and transplantation medicine. French immunologist Divi Cornec notes that “a defect in regulatory T-cells” can worsen autoimmune diseases and that these cells also play a “crucial role in preventing transplanted organs from being rejected” .

Conversely, cancer can “hijack” regulatory T cells to evade immune surveillance . When this occurs, Tregs become overzealous security guards, suppressing the immune system excessively and allowing tumors to grow unchecked . This dual role in preventing both excessive and insufficient immunity makes Tregs a critical therapeutic target for various conditions.

Current Research and Future Directions

The clinical potential of regulatory T cells is rapidly expanding, with over 200 clinical trials currently testing Treg-based treatments . These investigations span multiple therapeutic areas:

• Autoimmune Diseases: Enhancing Treg function or numbers may offer new treatments for conditions like rheumatoid arthritis and systemic lupus erythematosus .
• Transplantation Medicine: Infusing expanded Tregs may help induce immune tolerance to transplanted organs, potentially reducing or eliminating the need for lifelong immunosuppressive drugs .
• Cancer Therapy: Strategies that temporarily inhibit Treg activity in tumor environments may enhance anti-tumor immunity, while CAR-Treg technology aims to develop precisely targeted regulatory cells .

Chinese scientists have made significant contributions to this field. The discovery of CD8 Trp cells represents a major advancement in understanding how immune homeostasis is maintained . In addition, researchers such as Professor Zheng Songguo of Shanghai Jiao Tong University have found that all-trans retinoic acid can preserve the suppressive function of human natural regulatory T cells in inflammatory environments, and related clinical projects are now advancing .

The Path Forward

Despite the excitement surrounding regulatory T cells, researchers acknowledge that important questions remain. Scientists are still working to understand the differentiation mechanisms of CD8 Trp cells under pathological conditions, how to expand them safely and efficiently outside the body, and their specific roles in different diseases, including cancer and infections .

The research team led by Huang Xiaojun and Zhao Xiangyu is now focusing on optimizing the conditions for inducing CD8 Trp cell differentiation, exploring ways to enhance their FOXP3 expression capacity through cytokines such as TGF-β or gene editing, and conducting clinical trials to verify their efficacy in transplantation and autoimmune diseases .

As we continue to unravel the complexities of regulatory T cells, we move closer to harnessing their power for innovative therapies that maintain immune balance—the essential condition for health. The recognition of this groundbreaking discovery with a Nobel Prize underscores its transformative potential in medicine and in our fundamental understanding of human biology.

As Sakaguchi expressed upon receiving the Nobel award, he hopes this recognition will spur progress “in a direction where it can be applied in actual bedside and clinical settings” . With dedicated researchers worldwide building upon the foundation laid by these Nobel laureates, that hope appears increasingly within reach.